ライフサイエンスコーパス: pneumonic

1 ndular (25%) forms of tularemia, followed by pneumonic (12%), typhoidal (10%), oculoglandular (3%), a

2 Most patients had primary bubonic (63%), pneumonic (21%), or septicemic (5%) plague, with associa

3 ar dendritic cell subset, the tipDCs, in the pneumonic airways.

4 ogenicity, leading to protection against the pneumonic and bubonic forms of plague.

5 achieve its full pathogenic ability in both pneumonic and bubonic plague in C57BL/6J mice.

6 opositive animals detected in 9/9 versus 0/9 pneumonic and nonpneumonic populations, respectively [P

7 e in models of bubonic plague but not in the pneumonic and septicemic forms of the disease.

8 rial growth and the development of fulminant pneumonic and septicemic plague.

9 cal form of plague, 93.6% were bubonic, 5.9% pneumonic, and 0.5% septicemic with associated case fata

10 Yersinia pestis causes bubonic, pneumonic, and septicemic plague, diseases that are rapi

11 ia pestis is the causative agent of bubonic, pneumonic, and septicemic plague.

12 Yersinia pestis causes bubonic, pneumonic, and septicemic plague.

13 enic wild-type (WT) bacterium in bubonic and pneumonic animal models (mouse and rat) of plague.

14 MCs were localised at pneumonic areas, in the granuloma periphery and particul

15 In a mouse model of pneumonic B. mallei infection, we found that both MCP-1(

16 hanisms required to generate protection from pneumonic B. mallei infection.

17 tical chemokine required for protection from pneumonic B. mallei infection.

18 MyD88-dependent pathways may be important in pneumonic B. thailandensis infection but that MyD88-inde

19 ng a protective function of MGL1 in an acute pneumonic bacterial infection.

20 Pneumonic BALF, but not S. pneumoniae, induced degradati

21 presence of M. ovipneumoniae in the lungs of pneumonic bighorn sheep in this study, and M. ovipneumon

22 high-quality diagnostic specimens from nine pneumonic bighorn sheep in three populations and analyze

23 sights into the host-pathogen interaction in pneumonic Burkholderia infection.

24 icrobials, thus making it difficult to treat pneumonic Burkholderia infections.

25 ic nature of outbreaks and the low number of pneumonic cases of disease, we sought FDA approval of an

26 Following pneumonic challenge, the best efficacy was obtained in m

27 Pneumonic consolidation and mean virus titer in lung 7 d

28 here was moderate to severe inflammation and pneumonic consolidation in isolated areas at 5 and 7 day

29 patients from both outbreaks presented with pneumonic disease and although aerosol transmission has

30 Francisella tularensis causes acute, lethal pneumonic disease following infection with only 10 CFU.

31 vine respiratory tract prior to the onset of pneumonic disease is potentially due to bacterial invasi

32 For pneumonic disease specifically, ciprofloxacin may have s

33 ion to transmission-associated septicemic or pneumonic disease states.

34 Patients with pneumonic disease who received ciprofloxacin had no fata

35 f serotype A1 bacteria leads to the onset of pneumonic disease.

36 ceroglandular, oropharyngeal, glandular, and pneumonic disease.

37 infection but only slight attenuation by the pneumonic-disease model, closely mimicking the virulence

38 es and rabbits against challenge with lethal pneumonic doses of fully virulent Ames strain spores.

39 Progression of pneumonic extension >=0.5 lung fields per day compared t

40 microbiome and resistome of 38 subclinically pneumonic foals treated with either MaR (n = 19) or gall

41 horacic ultrasonography (i.e., subclinically pneumonic foals) is common in the United States.

42 ve agent of tularemia, is most deadly in the pneumonic form; therefore, mucosal immunity is an import

43 la pneumophila is the main cause of a severe pneumonic illness known as Legionnaires' disease and is

44 in the development of acute fibrinopurulent pneumonic infection in cattle.

45 immunity and IFN-gamma production following pneumonic infection with B. mallei and therefore may als

46 with the pathogen Salmonella Typhimurium or pneumonic infection with Burkholderia thailandensis, the

47 cells, NK cells, and NKT cells, during acute pneumonic infection with Klebsiella pneumoniae (KPn).

48 ng bubonic infection and in the lungs during pneumonic infection, suggesting a role for the Yaps duri

49 e of MGL1 in controlling neutrophilia during pneumonic infection, thus playing an important role in r

50 ed replication in respiratory airways during pneumonic infection.

51 Sepsis resulting from acute pneumonic infections by Gram-negative bacteria is often

52 t can cause severe, rapidly life-threatening pneumonic infections.

53 red in the murine bubonic (subcutaneous) and pneumonic (intranasal) plague infection models.

54 89.8%) than for urine from patients with non-pneumonic invasive infection (61.5%; P<0.05).

55 pha is required for the prompt resolution of pneumonic legionellosis and point to a direct role for T

56 alone or in combination with rF1, prevented pneumonic lesions and disease pathogenesis.

57 The pneumonic lesions and mortality caused by Mannheimia hae

58 tory disease and macroscopic and microscopic pneumonic lesions were more severe and persistent in M.

59 examination of the lungs and live imaging of pneumonic lesions, using a bioluminescent pneumococcus,

60 children presenting with uncomplicated (non-pneumonic) LRTI in primary care, overall and in key clin

61 quency CD8(+) tetramer(+) populations in the pneumonic lung and mediastinal lymph nodes fell rapidly

62 c sequences of two bovine isolates, one from pneumonic lung and the other from healthy prepuce, have

63 was detected as a predominant member of the pneumonic lung flora in lambs with early lesions of bron

64 onse profile in both lymphoid tissue and the pneumonic lung has no obvious deleterious consequences.

65 g lesions of these cattle with a majority of pneumonic lung lobes exhibiting fibronecrotic and exudat

66 magnitude of the inflammatory process in the pneumonic lung, though replication of this influenza vir

67 ffector T cell function and pathology in the pneumonic lung.

68 aged, "high-antigen load" environment of the pneumonic lung.

69 d virus-specific CD4+ T cell response in the pneumonic lung; 2) enhanced primary antiviral Ab-forming

70 neutrophils exhibited an increased influx in pneumonic lungs of K. pneumoniae-infected mice.

71 nfluenza epitope recovered directly from the pneumonic lungs of mice, this technique determined that

72 heimia haemolytica serotype A2 isolated from pneumonic lungs of two different ruminant species, one f

73 ating cytokine expressed in the airspaces of pneumonic lungs, but its physiological significance in t

74 A whole-body mouse model of pneumonic melioidosis was established for future evaluat

75 ts are confirmed using an experimental mouse pneumonic metastasis model.

76 eumonia but was ineffective against severely pneumonic mice, despite effective bacterial killing.

77 -dependent modifications in the airspaces of pneumonic mice, implicating a network of dispatched live

78 free beta-GlcCer accumulated in the lungs of pneumonic mice, which correlated with pulmonary NET form

79 he induction of select APPs in the livers of pneumonic mice.

80 roximately half of RSV-infected persons, and pneumonic opacities were typically small and unilateral.

81 nfected with a closely related gram-negative pneumonic organism (Klebsiella pneumoniae) suggesting th

82 echnology to render them less susceptible to pneumonic pasteurellosis and concomitant economic losses

83 One of the pathological hallmarks of bovine pneumonic pasteurellosis is an influx of neutrophils int

84 imia haemolytica is the etiological agent of pneumonic pasteurellosis of cattle and sheep; two differ

85 bronecrotic and exudative changes typical of pneumonic pasteurellosis, but other lung lobules had his

86 hospholipase products in the pathogenesis of pneumonic pasteurellosis, development and use of anti-in

87 to the pathogenesis of lung injury in bovine pneumonic pasteurellosis.

88 important role in the pathogenesis of bovine pneumonic pasteurellosis.

89 to the pathogenesis of lung injury in bovine pneumonic pasteurellosis.

90 ophysiological events associated with bovine pneumonic pasteurellosis.

91 ts in an acute respiratory disorder known as pneumonic pasteurellosis.

92 Pneumonic plague (PP), caused by Yersinia pestis, is the

93 Acute pneumonic plague accompanies the up-regulation of pro-in

94 rat as an alternative small animal model for pneumonic plague and characterized both the efficacy and

95 studying T-cell-mediated protection against pneumonic plague and demonstrates the capacity for live,

96 early host/pathogen interactions that define pneumonic plague and showcase the utility of human preci

97 ling early host/pathogen interactions during pneumonic plague and solidify the role of Pla in promoti

98 n CO92 and screened them in a mouse model of pneumonic plague at a dose equivalent to 5 50% lethal do

99 dicate that Y. pestis was capable of causing pneumonic plague before it evolved to optimally cause in

100 lly virulent in animal models of bubonic and pneumonic plague but also break through immune responses

101 is essential for Y. pestis to cause primary pneumonic plague but is less important for dissemination

102 d Yersinia pestis confers protection against pneumonic plague but is not considered safe for general

103 ation protected mice from lethal bubonic and pneumonic plague caused by CO92, a wild-type F1+ strain,

104 rt the use of gepotidacin as a treatment for pneumonic plague caused by Y. pestis.

105 Development of this new agent to treat pneumonic plague caused by Yersinia pestis depends on th

106 ation resulted in partial protection against pneumonic plague challenge with 250 MLD Y. pestis CO92,

107 responses and protection against bubonic and pneumonic plague challenges, with 80% and 90% survival,

108 o longer responsible for pandemic outbreaks, pneumonic plague continues to be a challenge for medical

109 side-ciprofloxacin group died, and secondary pneumonic plague developed in 3 patients in each group.

110 ague have highlighted a significant role for pneumonic plague during outbreaks of Y. pestis infection

111 lence testing in mouse models of bubonic and pneumonic plague found only a modest increase in surviva

112 course, severity, and difficulty of treating pneumonic plague highlight how differences in the route

113 severely attenuated Y. pestis CO92 to evoke pneumonic plague in a mouse model while retaining the re

114 ighly attenuated in evoking both bubonic and pneumonic plague in a mouse model.

115 in are fully effective treatment options for pneumonic plague in AGMs.

116 The mean lethal dose (MLD) for pneumonic plague in guinea pigs was estimated to be 1000

117 Yersinia pestis causes primary pneumonic plague in many mammalian species, including hu

118 ented Y. pestis were reported to cause fatal pneumonic plague in mice, suggesting a useful model for

119 in virulence for bubonic plague but not for pneumonic plague in mice.

120 s conferred comprehensive protection against pneumonic plague in naive recipient mice.

121 To develop an alternative to pneumonic plague in nonhuman primates, we explored guine

122 ting type III secretion in the prevention of pneumonic plague in rats and reveal critical contributio

123 Pneumonic plague is a deadly respiratory disease caused

124 Human pneumonic plague is a devastating and transmissible dise

125 Disease progression of primary pneumonic plague is biphasic, consisting of a preinflamm

126 Pneumonic plague is one of the world's most deadly infec

127 The AGM model of pneumonic plague is reproducible, well-characterized, an

128 Pneumonic plague is the deadliest form of disease caused

129 Although pneumonic plague is the deadliest manifestation of disea

130 Pneumonic plague is the most severe manifestation of pla

131 Primary pneumonic plague is transmitted easily, progresses rapid

132 Pla, its precise role in the pathogenesis of pneumonic plague is yet to be defined.

133 rovide 90 to 100% survivability to mice in a pneumonic plague model at 20 to 50 LD50.

134 double mutant was still fully virulent in a pneumonic plague model but had an approximately 90-fold

135 he Deltalpp or DeltamsbB single mutant, in a pneumonic plague model were significantly protected agai

136 Surprisingly, via intranasal instillation (pneumonic plague model), we saw a difference in the viru

137 In murine pneumonic plague models, passive transfer of convalescen

138 virulence of Y. pestis in either bubonic or pneumonic plague models.

139 In a parallel study with the pneumonic plague mouse model, after 72 h postinfection,

140 tion mutant was decreased about 10-fold in a pneumonic plague mouse model.

141 also attenuated (40 to 100%) at 12 LD50 in a pneumonic plague mouse model.

142 caf mutant was as virulent as WT CO92 in the pneumonic plague mouse model; however, it was attenuated

143 mized, controlled efficacy trials in the AGM pneumonic plague nonhuman primate model together with th

144 portant role for RovA in bubonic plague than pneumonic plague or systemic infection.

145 ernative small animal model for the study of pneumonic plague pathogenesis and immunity.

146 ptb1(pYA5199) play a protective role against pneumonic plague remains unclear.

147 Pneumonic plague represents the most severe form of dise

148 We hypothesized that the pathophysiology of pneumonic plague resulting from expression of proteins e

149 Pneumonic plague resulting from Yersinia pestis induces

150 t is less important for dissemination during pneumonic plague than during bubonic plague.

151 ulence factors required for the induction of pneumonic plague that are independent of iron scavenging

152 can green monkey (AGM) inhalational model of pneumonic plague to test the efficacy of gepotidacin.

153 utant and comparing its ability in mediating pneumonic plague to that of the wild type in two animal

154 rtant new target for developing an effective pneumonic plague vaccine.

155 ary Y. pestis challenge, and we suggest that pneumonic plague vaccines should aim to induce mixed typ

156 vations strongly suggest that development of pneumonic plague vaccines should strive to prime both CD

157 To aid the development of safe and effective pneumonic plague vaccines, we are deciphering mechanisms

158 y host response during the course of primary pneumonic plague was investigated in two mouse strains,

159 The AGM model of pneumonic plague was used to explore the effect of delay

160 illation, these rats rapidly developed fatal pneumonic plague within 2 to 4 days of infection.

161 ulmonary infection by Yersinia pestis causes pneumonic plague, a necrotic bronchopneumonia that is ra

162 Vaccines against primary pneumonic plague, a potential bioweapon, must be tested

163 of the bacterium Yersinia pestis causes the pneumonic plague, a rapidly fatal disease.

164 ulmonary infection by Yersinia pestis causes pneumonic plague, a rapidly progressing and often fatal

165 pestis is the causative agent of bubonic and pneumonic plague, an acute and often fatal disease in hu

166 am-negative bacterium Yersinia pestis causes pneumonic plague, an acutely lethal septic pneumonia.

167 he potential virulence properties of Psa for pneumonic plague, an Escherichia coli strain expressing

168 Pneumonic plague, an often-fatal disease for which no va

169 on with the bacterium Yersinia pestis causes pneumonic plague, an often-fatal disease for which no va

170 ficantly affected by the Pla protease during pneumonic plague, and although A2AP participates in immu

171 ynergistically in protecting animals against pneumonic plague, and we have demonstrated an immunologi

172 onsequences of neutrophil recruitment during pneumonic plague, and we studied the susceptibility of C

173 rsinia pestis-laden aerosols that results in pneumonic plague, arming both the mucosal and systemic i

174 s protective immunity to prevent bubonic and pneumonic plague, as well as yersiniosis, in mice and wo

175 uvant to enhance protective immunity against pneumonic plague, but in a dose-dependent fashion.

176 Pneumonic plague, caused by inhalation of Yersinia pesti

177 Pneumonic plague, caused by Yersinia pestis, is a rapidl

178 is review we describe the characteristics of pneumonic plague, focusing on its disease progression an

179 Yersinia pestis, which causes bubonic and pneumonic plague, forms pigmented red colonies on Congo

180 For pneumonic plague, immunized mice required immunity to bo

181 deeply rooted strains of Y. pestis to cause pneumonic plague, indicating that Y. pestis was primed t

182 m-negative bacterium that causes bubonic and pneumonic plague, is able to rapidly disseminate to othe

183 In a coinfection model of pneumonic plague, it appears that Yersinia pestis quickl

184 Despite the importance of pneumonic plague, little is known of the early pulmonary

185 t failure defined as death, fever, secondary pneumonic plague, or alternative or prolonged plague tre

186 that protect mice against bubonic plague and pneumonic plague, suggesting that rV10 may serve as an i

187 ared to the WT bacterium in a mouse model of pneumonic plague, the Deltalpp Deltaail double mutant an

188 Additional treatment options for pneumonic plague, the most severe form of infection by Y

189 le this modification is unnecessary to cause pneumonic plague, the substitution is instead needed to

190 tis virulence in mouse models of bubonic and pneumonic plague, we characterized an msbB in-frame dele

191 sing the C57BL/6 mouse models of bubonic and pneumonic plague, we determined that all of these genes

192 produces a severe primary pneumonia known as pneumonic plague, which is contagious and highly lethal

193 esidues 271-300, elicited protection against pneumonic plague, which seemed to be based on conformati

194 , Yersinia-specific sRNA in a mouse model of pneumonic plague.

195 positive strains of Y. pestis in bubonic and pneumonic plague.

196 th Yersinia pestis, the agent of bubonic and pneumonic plague.

197 a live attenuated cell-based vaccine against pneumonic plague.

198 bt, that plays a role in the pathogenesis of pneumonic plague.

199 anism and the causative agent of bubonic and pneumonic plague.

200 for virulence in mouse models of bubonic and pneumonic plague.

201 the use of an iron dextran-treated model of pneumonic plague.

202 pigmented Yersinia pestis does not result in pneumonic plague.

203 e was no disease pathology characteristic of pneumonic plague.

204 tis primes T cells that protect mice against pneumonic plague.

205 n in virulence in mouse models of bubonic or pneumonic plague.

206 derivative, V10, to protect these rats from pneumonic plague.

207 to become the causative agent of bubonic and pneumonic plague.

208 sease that can manifest as either bubonic or pneumonic plague.

209 and F1 antigens protected mice in a model of pneumonic plague.

210 ce for the pathogenesis of plague, including pneumonic plague.

211 e cells to vaccine-primed protection against pneumonic plague.

212 . pestis infection, an experimental model of pneumonic plague.

213 terized an intranasal mouse model of primary pneumonic plague.

214 llular immunity will most effectively combat pneumonic plague.

215 fferentiation primary response 88 (MyD88) in pneumonic plague.

216 ion, protected mice in models of bubonic and pneumonic plague.

217 stis KIM, the etiologic agent of bubonic and pneumonic plague.

218 of Yersinia pestis, the agent of bubonic and pneumonic plague.

219 ormation and expansion or protection against pneumonic plague.

220 able inflammatory responses to cause primary pneumonic plague.

221 bacterium Yersinia pestis results in primary pneumonic plague.

222 m that is the causative agent of bubonic and pneumonic plague.

223 CO92 in mouse and rat models of bubonic and pneumonic plague.

224 . pestis CO92 in mouse models of bubonic and pneumonic plague.

225 dent manner in the lungs during experimental pneumonic plague.

226 able impact on the progression or outcome of pneumonic plague.

227 pestis causes the fatal respiratory disease pneumonic plague.

228 nuation at 11 or 12 LD50 in a mouse model of pneumonic plague.

229 3SS as a potential vaccine candidate against pneumonic plague.

230 icantly protected from developing subsequent pneumonic plague.

231 pha and IFN-gamma in protecting mice against pneumonic plague.

232 d for production of bubonic, septicemic, and pneumonic plague.

233 a pestis, the causative agent of bubonic and pneumonic plague.

234 mportant for development of both bubonic and pneumonic plague.

235 ing specific roles for these pathways during pneumonic plague.

236 d lethality in murine models of systemic and pneumonic plague.

237 ironment during the preinflammatory phase of pneumonic plague.

238 protease is essential for the development of pneumonic plague; however, the complete repertoire of su

239 a pestis, the causative agent of bubonic and pneumonic plagues, has undergone detailed study at the m

240 pestis is the etiologic agent of bubonic and pneumonic plagues.

241 redict the ventilatory support need based on pneumonic progression of COVID-19 on consecutive chest X

242 role of the C-type lectin receptor Mincle in pneumonic sepsis caused by K. pneumoniae.

243 uses Gram-negative lung infections and fatal pneumonic sepsis for which limited therapeutic options a

244 In a murine model of pneumonic sepsis using pulmonary infection with Klebsiel

245 se-type lectin-1 (MGL1), a mammalian CLR, in pneumonic sepsis, a deadly immune disorder frequently as

246 e a critical cellular population to regulate pneumonic sepsis.

247 ating nociceptors promote CRKP pneumonia and pneumonic sepsis.

248 tidrug-resistant Gram-negative infection and pneumonic sepsis.

249 il sequestration and edema formation at that pneumonic site with or without pretreatment with endotox

250 e 14th century are inconsistent with direct (pneumonic) transmission.

251 onducted a case-control study of adults with pneumonic tularemia and investigated the environment to

252 on of Francisella tularensis biovar A causes pneumonic tularemia associated with high morbidity and m

253 The development of a vaccine against pneumonic tularemia has been limited by a lack of inform

254 Study of this outbreak of primary pneumonic tularemia implicates lawn mowing and brush cut

255 ated as potential vaccine candidates against pneumonic tularemia in experimental animals.

256 We now report the natural history of pneumonic tularemia in female Fischer 344 rats after nos

257 Although primary pneumonic tularemia in humans typically occurs by inhala

258 Inhalation of Francisella tularensis causes pneumonic tularemia in humans, a severe disease with a 3

259 Overall, the pathogenesis of pneumonic tularemia in the female F344 rat model appears

260 The only previously reported outbreak of pneumonic tularemia in the United States also occurred o

261 Pneumonic tularemia is a life-threatening disease caused

262 Pneumonic tularemia is caused by inhalation of Francisel

263 The incidence of pneumonic tularemia is very low; therefore, it is not fe

264 n the summer of 2000, an outbreak of primary pneumonic tularemia occurred on Martha's Vineyard, Massa

265 ar results were obtained in a mouse model of pneumonic tularemia using the highly virulent F. tularen

266 mutant because this strain was attenuated in pneumonic tularemia yet induced a protective immune resp

267 profloxacin were efficacious in treatment of pneumonic tularemia, although clearance of bacteria may

268 Inhalational pneumonic tularemia, caused by Francisella tularensis, i

269 eyard who had symptoms suggestive of primary pneumonic tularemia, were ill between May 15 and October

270 was severely reduced in the murine model of pneumonic tularemia.

271 f chicken embryos and in the murine model of pneumonic tularemia.

272 ligand on resistance to F. novicida-induced pneumonic tularemia.

273 novicida, leading to protective immunity to pneumonic tularemia.

274 rtant role in tempering the host response to pneumonic tularemia.

275 ronment to identify risk factors for primary pneumonic tularemia.

276 th tularemia; 11 of these cases were primary pneumonic tularemia.

277 r to qualify the cynomolgus macaque model of pneumonic tularemia.

278 ting novel vaccines and therapeutics against pneumonic tularemia.

279 vere tissue damage that characterizes lethal pneumonic tularemia.

280 ompared to the wild type in a mouse model of pneumonic tularemia.

281 n of this agent with bronchopneumonia (16/34 pneumonic versus 0/17 nonpneumonic sheep were PCR positi